BioNTech SE - ADR

NASDAQ:BNTX   3:59:56 PM EDT
353.11
+13.85 (+4.08%)
4:02:43 PM EDT: $353.32 +0.21 (+0.06%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)85.63B
Current PE21.03
Forward PE 8.62
2yr Forward PE 8.05
See more stats
Estimates Current Quarter
Revenue$5.67 Billion
Adjusted EPS$11.62
See more estimates
10-Day MA$348.23
50-Day MA$341.55
200-Day MA$196.24
See more pivots

BioNTech SE - ADR Stock, NASDAQ:BNTX

An der Goldgrube 12, Mainz, Rheinland-Pfalz 55131
Germany
Phone: +49.6131.9084.0
Number of Employees: 1941

Description

BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. It exploits an array of discovery and therapeutic drug platforms for the development of novel biopharmaceuticals. The company's portfolio of infectious disease and oncology product candidates include FixVac, iNeST (Individualized Neoantigen Specific Immunotherapy), Intratumoral Immunotherapies, RiboMabs, RiboCytokines, CAR T Cell Platform, T Cell Receptor(TCR), Checkpoint Immunomodulator, Targeted Cancer Antibodies, and Small Molecule Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.